| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | OLEOLIVE, INC. | 2031 KINGS HWY | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R41CA268286 | Chemosensitization of Glioblastoma by Propentofylline | 000 | 1 | NIH | 10/24/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,040,302 ) |
| | 2023 | 2023 | OLEOLIVE, INC. | 2031 KINGS HWY | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R42AG065069 | Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease | 002 | 4 | NIH | 9/20/2023 | $249,774 |
| | 2023 | 2023 | OLEOLIVE, INC. | 2031 KINGS HWY | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R42AG065069 | Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease | 001 | 4 | NIH | 5/4/2023 | $805,761 |
| | 2023 | 2022 | OLEOLIVE, INC. | 2031 KINGS HWY | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R42AG065069 | Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease | 000 | 3 | NIH | 1/26/2023 | $0 |
| | 2023 | 2021 | OLEOLIVE, INC. | 2031 KINGS HWY | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R41CA247025 | Oleocanthal functional food products for breast cancer recurrence control | 000 | 1 | NIH | 5/9/2023 | -$15,233 |
|
| Issue Date FY: 2022 ( Subtotal = $2,092,438 ) |
| | 2022 | 2022 | OLEOLIVE, INC. | 2031 KINGS HWY | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R41CA268286 | Chemosensitization of Glioblastoma by Propentofylline | 001 | 1 | NIH | 8/22/2022 | $0 |
| | 2022 | 2022 | OLEOLIVE, INC. | 2031 KINGS HWY STE 236 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R41CA268286 | Chemosensitization of Glioblastoma by Propentofylline | 000 | 1 | NIH | 8/9/2022 | $399,998 |
| | 2022 | 2022 | OLEOLIVE, INC. | 2031 KINGS HWY | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R42AG065069 | Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease | 001 | 3 | NIH | 9/22/2022 | $0 |
| | 2022 | 2022 | OLEOLIVE, INC. | 2031 KINGS HWY | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R42AG065069 | Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease | 000 | 3 | NIH | 9/9/2022 | $1,692,440 |
|
| Issue Date FY: 2021 ( Subtotal = $51,632 ) |
| | 2021 | 2021 | OLEOLIVE, LLC | 2031 KINGS HWY # 204 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R41CA247025 | Oleocanthal functional food products for breast cancer recurrence control | 000 | 1 | NIH | 5/14/2021 | $54,756 |
| | 2021 | 2020 | OLEOLIVE, INC. | 2031 KINGS HWY STE 236 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R43AG065069 | Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer?s Disease | 000 | 2 | NIH | 5/24/2021 | -$3,094 |
| | 2021 | 2019 | OLEOLIVE, INC. | 2031 KINGS HWY STE 236 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R43AG061952 | Evaluation of oral oleocanthal to prevent and/or treat Alzheimer?s disease and related dementias | 000 | 2 | NIH | 6/15/2021 | -$30 |
|
| Issue Date FY: 2020 ( Subtotal = $503,007 ) |
| | 2020 | 2020 | OLEOLIVE, LLC | 2031 KINGS HWY # 204 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R43AG065069 | Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer?s Disease | 000 | 2 | NIH | 5/20/2020 | $103,008 |
| | 2020 | 2020 | OLEOLIVE, LLC | 2031 KINGS HWY # 204 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R41CA247025 | Oleocanthal functional food products for breast cancer recurrence control | 000 | 1 | NIH | 6/1/2020 | $399,999 |
|
| Issue Date FY: 2019 ( Subtotal = $414,004 ) |
| | 2019 | 2019 | OLEOLIVE, LLC | 2031 KINGS HWY # 204 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R43AG061952 | Evaluation of oral oleocanthal to prevent and/or treat Alzheimer?s disease and related dementias | 000 | 2 | NIH | 5/27/2019 | $67,013 |
| | 2019 | 2019 | OLEOLIVE, LLC | 2031 KINGS HWY # 204 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R43AG065069 | Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer?s Disease | 000 | 1 | NIH | 8/19/2019 | $346,991 |
| | 2019 | 2019 | OLEOLIVE, LLC | 2031 KINGS HWY # 204 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R43AG065069 | Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer?s Disease | 001 | 1 | NIH | 9/20/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $269,634 ) |
| | 2018 | 2018 | OLEOLIVE, LLC | 2031 KINGS HWY # 204 | SHREVEPORT | LA | 71103-3600 | CADDO | USA | R43AG061952 | Evaluation of oral oleocanthal to prevent and/or treat Alzheimer?s disease and related dementias | 000 | 1 | NIH | 9/18/2018 | $269,634 |
|
|
